Renal Cluster Drug Development Pipeline Review, 2017

Publisher Name :
Date: 11-May-2017
No. of pages: 181

Renal Cluster Drug Development Pipeline Review, 2017

Summary

This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. There are a total of 36 products in development for this indication, by 34 companies and one academic institution. A number of companies are operating in this space, with A1M Pharma alone developing multiple programs within the area.

Finally, kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Due to differences between the two patients, an autoimmune reaction against the donor kidney may occur in the recipient. There are a total of 39 products in development for this indication, by 33 companies and two academic institutions. Key companies operating in this pipeline space include Astellas Pharma, GlaxoSmithKline, Hillhurst Biopharmaceuticals and Kyowa Hakko Kirin.

While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors.

Scope

- Which companies are the most active within the pipeline for renal cluster therapeutics?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in the field of renal cluster therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Renal Cluster Drug Development Pipeline Review, 2017

Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 10
Introduction 11
GBI Research Report Coverage 11
Kidney Fibrosis - Overview 11
Chronic Kidney Disease (Chronic Renal Failure) - Overview 11
Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11
Kidney Transplant Rejection - Overview 11
Therapeutics Development 12
Kidney Fibrosis 12
Chronic Kidney Disease (Chronic Renal Failure) 18
Acute Renal Failure (ARF) (Acute Kidney Injury) 27
Kidney Transplant Rejection 34
Therapeutics Assessment 41
Kidney Fibrosis 41
Chronic Kidney Disease (Chronic Renal Failure) 51
Acute Renal Failure (ARF) (Acute Kidney Injury) 61
Kidney Transplant Rejection 69
Companies Involved in Therapeutics Development 77
Kidney Fibrosis 77
Chronic Kidney Disease (Chronic Renal Failure) 87
Acute Renal Failure (ARF) (Acute Kidney Injury) 106
Kidney Transplant Rejection 120
Dormant Projects 132
Kidney Fibrosis 132
Chronic Kidney Disease (Chronic Renal Failure) 133
Acute Renal Failure (ARF) (Acute Kidney Injury) 135
Kidney Transplant Rejection 136
Discontinued Products 138
Chronic Kidney Disease (Chronic Renal Failure) 138
Acute Renal Failure (ARF) (Acute Kidney Injury) 139
Kidney Transplant Rejection 139
Product Development Milestones 140
Kidney Fibrosis 140
Chronic Kidney Disease (Chronic Renal Failure) 148
Acute Renal Failure (ARF) (Acute Kidney Injury) 161
Kidney Transplant Rejection 170
Appendix 180
Methodology 180
Coverage 180
Secondary Research 180
Primary Research 180
Expert Panel Validation 180
Contact Us 181
Disclaimer 181

List of Tables
Number of Products under Development for Kidney Fibrosis 12
Number of Products under Development by Companies, Kidney Fibrosis 14
Number of Products under Development by Universities/Institutes, Kidney Fibrosis 15
Products under Development by Companies, Kidney Fibrosis 16
Products under Development by Universities/Institutes, Kidney Fibrosis 17
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 18
Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 20
Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 22
Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 23
Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 26
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) 27
Number of Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury) 29
Number of Products under Development by Universities/Institutes, Acute Renal Failure (ARF) (Acute Kidney Injury) 30
Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury) 31
Products under Development by Universities/Institutes, Acute Renal Failure (ARF) (Acute Kidney Injury) 33
Number of Products under Development for Kidney Transplant Rejection 34
Number of Products under Development by Companies, Kidney Transplant Rejection 36
Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 37
Products under Development by Companies, Kidney Transplant Rejection 38
Products under Development by Universities/Institutes, Kidney Transplant Rejection 40
Number of Products by Stage and Target, Kidney Fibrosis 42
Number of Products by Stage and Mechanism of Action, Kidney Fibrosis 45
Number of Products by Stage and Route of Administration, Kidney Fibrosis 48
Number of Products by Stage and Molecule Type, Kidney Fibrosis 50
Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure) 52
Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure) 55
Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure) 58
Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure) 60
Number of Products by Stage and Target, Acute Renal Failure (ARF) (Acute Kidney Injury) 62
Number of Products by Stage and Mechanism of Action, Acute Renal Failure (ARF) (Acute Kidney Injury) 64
Number of Products by Stage and Route of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury) 66
Number of Products by Stage and Molecule Type, Acute Renal Failure (ARF) (Acute Kidney Injury) 68
Number of Products by Stage and Target, Kidney Transplant Rejection 70
Number of Products by Stage and Mechanism of Action, Kidney Transplant Rejection 72
Number of Products by Stage and Route of Administration, Kidney Transplant Rejection 74
Number of Products by Stage and Molecule Type, Kidney Transplant Rejection 76
Kidney Fibrosis - Pipeline by AbbVie Inc 77
Kidney Fibrosis - Pipeline by Allergan Plc 77
Kidney Fibrosis - Pipeline by Angion Biomedica Corp 78
Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc 78
Kidney Fibrosis - Pipeline by BiOrion Technologies BV 79
Kidney Fibrosis - Pipeline by Cellmid Ltd 79
Kidney Fibrosis - Pipeline by Epigen Biosciences Inc 80
Kidney Fibrosis - Pipeline by Evotec AG 80
Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc 81
Kidney Fibrosis - Pipeline by GenKyoTex SA 81
Kidney Fibrosis - Pipeline by Horizon Pharma Plc 82
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc 82
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH 83
Kidney Fibrosis - Pipeline by MorphoSys AG 83
Kidney Fibrosis - Pipeline by Pharmaxis Ltd 84
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc 84
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc 85
Kidney Fibrosis - Pipeline by Sirnaomics Inc 85
Kidney Fibrosis - Pipeline by Symic Biomedical Inc 86
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd 86
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp 87
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH 87
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc 88
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc 88
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG 89
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BLR Bio LLC 89
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH 90
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd 90
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd 91
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd 91
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Complexa Inc 92
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Corp 92
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp 93
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG 93
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by F. Hoffmann-La Roche Ltd 94
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc 94
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd 95
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd 95
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd 96
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nippon Zoki Pharmaceutical Co Ltd 96
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG 97
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd 97
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prismic Pharmaceuticals Inc 98
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC 98
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc 99
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc 99
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Regulus Therapeutics Inc 100
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc 100
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp 101
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Spotlight Innovation Inc 101
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Co Ltd 102
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc 102
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc 103
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc 103
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences 104
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd 104
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB 105
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB 106
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV 106
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma BV 107
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp 107
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Atox Bio Ltd 108
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Ltd 108
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Complexa Inc 109
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Therapeutics Inc 109
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DURECT Corp 110
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Evotec AG 110
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Exponential Biotherapies Inc 111
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd 111
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics Inc 112
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma Inc 112
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Mitotech SA 113
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex Inc 113
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NeuroVive Pharmaceutical AB 114
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV 114
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ProMetic Life Sciences Inc 115
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals Inc 115
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Rediscovery Life Sciences 115
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Regulus Therapeutics Inc 116
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by SBI Pharmaceuticals Co Ltd 116
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Spherium Biomed SL 117
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics Inc 117
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Stealth BioTherapeutics Inc 118
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos Therapeutics Inc 118
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Ltd 119
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Xigen SA 119
Kidney Transplant Rejection - Pipeline by Amgen Inc 120
Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp 120
Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc 121
Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc 121
Kidney Transplant Rejection - Pipeline by Biogen Inc 122
Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc 122
Kidney Transplant Rejection - Pipeline by Corline Biomedical AB 123
Kidney Transplant Rejection - Pipeline by CSL Ltd 123
Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc 124
Kidney Transplant Rejection - Pipeline by Grifols SA 124
Kidney Transplant Rejection - Pipeline by Hansa Medical AB 125
Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd 125
Kidney Transplant Rejection - Pipeline by Magnus Life Ltd 126
Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG 126
Kidney Transplant Rejection - Pipeline by Novartis AG 127
Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd 127
Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics 128
Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd 128
Kidney Transplant Rejection - Pipeline by Pharming Group NV 129
Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC 129
Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc 130
Kidney Transplant Rejection - Pipeline by Shire Plc 130
Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc 131
Kidney Fibrosis - Dormant Projects 132
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 133
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 135
Kidney Transplant Rejection - Dormant Projects 136
Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products 138
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 139
Kidney Transplant Rejection - Discontinued Products 139

List of Figures
Number of Products under Development for Kidney Fibrosis 12
Number of Products under Development by Companies, Kidney Fibrosis 13
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 18
Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 19
Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 22
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) 27
Number of Products under Development by Companies, Acute Renal Failure (ARF) (Acute Kidney Injury) 28
Number of Products under Development for Kidney Transplant Rejection 34
Number of Products under Development by Companies, Kidney Transplant Rejection 35
Number of Products under Development by Universities/Institutes, Kidney Transplant Rejection 37
Number of Products by Top 10 Targets, Kidney Fibrosis 41
Number of Products by Stage and Top 10 Targets, Kidney Fibrosis 41
Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis 44
Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis 44
Number of Products by Routes of Administration, Kidney Fibrosis 47
Number of Products by Stage and Routes of Administration, Kidney Fibrosis 47
Number of Products by Molecule Types, Kidney Fibrosis 49
Number of Products by Stage and Molecule Types, Kidney Fibrosis 49
Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 51
Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 51
Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 54
Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 54
Number of Products by Top 10 Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 57
Number of Products by Stage and Top 10 Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 57
Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 59
Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 59
Number of Products by Top 10 Targets, Acute Renal Failure (ARF) (Acute Kidney Injury) 61
Number of Products by Stage and Top 10 Targets, Acute Renal Failure (ARF) (Acute Kidney Injury) 61
Number of Products by Top 10 Mechanism of Actions, Acute Renal Failure (ARF) (Acute Kidney Injury) 63
Number of Products by Stage and Top 10 Mechanism of Actions, Acute Renal Failure (ARF) (Acute Kidney Injury) 63
Number of Products by Routes of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury) 65
Number of Products by Stage and Routes of Administration, Acute Renal Failure (ARF) (Acute Kidney Injury) 65
Number of Products by Molecule Types, Acute Renal Failure (ARF) (Acute Kidney Injury) 67
Number of Products by Stage and Molecule Types, Acute Renal Failure (ARF) (Acute Kidney Injury) 67
Number of Products by Top 10 Targets, Kidney Transplant Rejection 69
Number of Products by Stage and Top 10 Targets, Kidney Transplant Rejection 69
Number of Products by Top 10 Mechanism of Actions, Kidney Transplant Rejection 71
Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Transplant Rejection 71
Number of Products by Routes of Administration, Kidney Transplant Rejection 73
Number of Products by Stage and Routes of Administration, Kidney Transplant Rejection 73
Number of Products by Top 10 Molecule Types, Kidney Transplant Rejection 75
Number of Products by Stage and Top 10 Molecule Types, Kidney Transplant Rejection 75

  • Global Peritoneal Dialysis Solution Sales Market Report 2017
    Published: 13-Nov-2017        Price: US 4000 Onwards        Pages: 109
    In this report, the global Peritoneal Dialysis Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peritoneal Dialysis Solution for these regions, from 2012 to 2022 (forecast), covering - United States - China - ......
  • Nephrotic Syndrome - Pipeline Review, H2 2017
    Published: 07-Nov-2017        Price: US 2000 Onwards        Pages: 55
    Nephrotic Syndrome - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H2 2017, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape. Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of sma......
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2017
    Published: 07-Nov-2017        Price: US 2000 Onwards        Pages: 47
    End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2017, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genito Urinary System And Sex Hormones) pipeline landscape. End-stage kidney disease is the complete or ......
  • United States Peritoneal Dialysis Solution Market Report 2017
    Published: 02-Nov-2017        Price: US 3800 Onwards        Pages: 102
    In this report, the United States Peritoneal Dialysis Solution market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and gr......
  • Chronic Kidney Disease (Chronic Renal Failure) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
    Published: 01-Nov-2017        Price: US 2000 Onwards        Pages: 60
    DelveInsight's, Chronic Kidney Disease (Chronic Renal Failure) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" report provides comprehensive insights about marketed and Phase III products for the Chronic Kidney Disease (Chronic Renal Failure). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. It also provides a comprehensive understanding of the emer......
  • Late-stage chronic kidney disease (CKD) -Epidemiology Forecast to 2025
    Published: 01-Nov-2017        Price: US 2750 Onwards        Pages: 40
    DelveInsight "Late-stage chronic kidney disease (CKD) - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Late-stage chronic kidney disease (CKD) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Late-stage chronic kidney disease (CKD) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden ......
  • Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Late-stage chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding ......
  • Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 01-Nov-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology and Market Forecast - 2025" Reports provides an overview of the disease and global market size of the Acute Renal Failure (ARF) (Acute Kidney Injury) for the 7MM (United States, Germany, France, Italy, Spain and UK). The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Acute Renal Failure (ARF) (Acute Kidney Injury) forecasted market share for ten years to......
  • Hyperoxaluria - Pipeline Insight, 2017
    Published: 01-Nov-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Hyperoxaluria-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Hyperoxaluria. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Hyperoxaluria by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a speci......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs